Sutro BioPharma Q3 revenue $25.1M, cash $287.3M; STRO-002 data at ASH, Phase 2 design by year end

SUTRO BIOPHARMA, INC.

2022-Q3 EPS reported -$1.74 revenue$59,140,000

Revenue $25.1M (up from $8.5M YoY); total operating expenses $46.4M.
Cash, equivalents and marketable securities $287.3M as of Sep 30, 2022; projected runway into first half 2024.
STRO-002 oral presentation at ASH 2022 for pediatric AML; Phase 1 ovarian data and Phase 2 design expected by end 2022.
Vaxcyte positive Phase 1/2 data for VAX-24; Sutro to receive 4% royalties on worldwide net sales.
Astellas collaboration with $90M upfront received; Merck $10M milestone triggered.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SUTRO BIOPHARMA, INC. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-023274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.